Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL in Non-Small Cell Lung Cancer
NCT07560111Phase 2Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nolgileucel in non-small cell lung cancer (NSCLC), sponsored by Juncell Therapeutics. Primary endpoints: Objective Response Rate at 18 weeks and Progression-Free Survival at 36 months. Started Jun 2026; status: recruiting.
02
Drugs
nolgileucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07560111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560111.